Abou Chakra M - Search Results

1

Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer.

Abou Chakra M, Packiam VT, O'Donnell MA. Abou Chakra M, et al. Expert Opin Pharmacother. 2023 Sep-Dec;24(18):2081-2091. doi: 10.1080/14656566.2023.2271396. Epub 2024 Jan 5. Expert Opin Pharmacother. 2023. PMID: 37842956 Review.

2

US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guérin-Unresponsive and Bacillus Calmette-Guérin-Exposed Nonmuscle-Invasive Bladder Cancer.

Abou Chakra M, Shore ND, Dillon R, O'Donnell MA. Abou Chakra M, et al. Urol Pract. 2024 Jan;11(1):97-107. doi: 10.1097/UPJ.0000000000000481. Epub 2023 Oct 30. Urol Pract. 2024. PMID: 37903746

3

Reply by Authors.

Abou Chakra M, Shore ND, Dillon R, O'Donnell MA. Abou Chakra M, et al. Urol Pract. 2024 Jan;11(1):108. doi: 10.1097/UPJ.0000000000000481.02. Epub 2023 Nov 2. Urol Pract. 2024. PMID: 37917624 No abstract available.

4

Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma.

McElree IM, Packiam VT, Steinberg RL, Hougen HY, Abou Chakra M, Mott SL, O'Donnell MA. McElree IM, et al. Among authors: abou chakra m. Cancers (Basel). 2024 Dec 10;16(24):4126. doi: 10.3390/cancers16244126. Cancers (Basel). 2024. PMID: 39766026 Free PMC article.

5

The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer.

Abou Chakra M, Packiam VT, McElree IM, Mott SL, O'Donnell MA. Abou Chakra M, et al. Urol Oncol. 2024 Nov 25:S1078-1439(24)00692-6. doi: 10.1016/j.urolonc.2024.10.012. Online ahead of print. Urol Oncol. 2024. PMID: 39592360

6

Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer.

Abou Chakra M, Luo Y, Duquesne I, A O'Donnell M. Abou Chakra M, et al. Front Biosci (Landmark Ed). 2024 Aug 21;29(8):295. doi: 10.31083/j.fbl2908295. Front Biosci (Landmark Ed). 2024. PMID: 39206898 Free article. Review.

7

Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor.

McElree IM, Packiam VT, Steinberg RL, Hougen HY, Mott SL, Abou Chakra M, Zakharia Y, O'Donnell MA. McElree IM, et al. Among authors: abou chakra m. Cancers (Basel). 2024 Jul 17;16(14):2561. doi: 10.3390/cancers16142561. Cancers (Basel). 2024. PMID: 39061200 Free PMC article.

8

A Multinational, Multi-Institutional Study Assessing the Impact of Diabetes Mellitus on the Prognosis of Patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.

Abou Chakra M, Duquesne I, Peyromaure M, Mott SL, Moussa M, O'Donnell MA. Abou Chakra M, et al. Nutr Cancer. 2024;76(9):861-869. doi: 10.1080/01635581.2024.2374046. Epub 2024 Jul 7. Nutr Cancer. 2024. PMID: 38973234

9

Establishing an Intravesical Doublet Chemotherapy Clinic for Nonmuscle-Invasive Bladder Cancer Patients.

Abou Chakra M, Shore ND, Brown ES, Du GJ, O'Donnell MA. Abou Chakra M, et al. Urol Pract. 2024 Jul;11(4):613-623. doi: 10.1097/UPJ.0000000000000576. Epub 2024 May 24. Urol Pract. 2024. PMID: 38899680 Review.

10

Reply by Authors.

Abou Chakra M, Shore ND, Brown ES, Du GJ, O'Donnell MA. Abou Chakra M, et al. Urol Pract. 2024 Jul;11(4):623. doi: 10.1097/UPJ.0000000000000592. Epub 2024 May 8. Urol Pract. 2024. PMID: 38899667 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters